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Failure of heparin to affect two types of experimental
glomerulonephritis in rabbits
WAYNE A. BORDER, CURTIS B. WILSON and FRANK J. DIxoN
Department of Immunopathology, Scripps Clinic and Research Foundation, La Jolla, California
Failure of heparin to affect two types of experimental glomerulo-
nephritis in rabbits. Anticoagulation has been reported to
ameliorate antiglomerular basement membrane glomerulonephri-
tis (anti-GBM-GN) while its effect on chronic immune complex
glomerulonephritis (lC-GN) as studied in the NZB mouse is
unclear. Chronic serum sickness IC-GN was induced in rabbits
by injecting bovine serum albumin (BSA) daily. Anti-GBM-
GN was induced by i.v. injection of a known amount of
heterologous anti-GBM antibody. Heparin was administered
beginning at two to six weeks after the first BSA injections or
before the administration of anti-GBM antibody, on various
schedules from 5000 U every 12 hr to 8000 U every 8 hr. With this
dosage the partial thromboplastin time remained greater than 1
to 2½ times the control at the time of the subsequent heparin injec-
tion. Heparinized and noriheparinized groups were matched
according to duration of disease, maximum anti-BSA concentra-
tions or anti-GBM antibody dosage—and no significant
differences were found in proteinuria; severity of the glomerular
histologic lesions; or immunofluorescence patterns of im-
munnglobulin G (IgG), third component of complement (C3),
BSA or fibrinogen-related antigen(s) (FRA). Crescent formation
was not prevented. This study shows that heparin in the maxtmum
permissible dosage is ineffective in preventing glomerular FRA
deposition or altering the progression of experimental lC-GN or
anti-GBM-GN in rabbits.
Echee de l'héparine dans deux variétés de gloméi-ulonepbrites ex-
périmentales chez le lapin. Il a été rapporté que le traitement an-
ticoagulant améliore l'évolution de Ia glomérulonéphrite par an-
ticorps anti membrane basale glomérulaire (anti GBM-GN) alors
que son efficacité sur Ia glomérulonephrite des complexes immuns
(IC-GN), tel qu'elle est étudiée chez Ia souris NZB, n'est pas nette.
Une maladie sérique chronique lC-GN a été réalist5e chez des
lapins par l'injection quotidienne de serum albumine bovine
(BSA). Des néphrites anti GBM-GN ont été obtenues par l'injec-
tion intraveineuse dune quantité déterminée d'anticorps anti
GBM hCtérologues. L'héparine a été administrée après un délai de
deux a six semaines par rapport a Ia premiere injection de BSA ou
avant l'injection d'anticorps anti GBM. DiffCrentes posologies al-
larit de 5000 unites toutes les 12 heures a 8000 unites toutes les 8
heures ont été utilisées. A ces doses le temps de thromboplastine est
supérieur a 1,5 a 2,5 fois le contrôle immédiatement avant une in-
jection d'hCparine. Les groupes héparinisés et non héparinisés ont
Cté ajustés en fonction de Ia durée de la maladie, do maximum de
concentration d'anticorps anti BSA ou anti GBM. Aucune differ-
ence signilicative n'a été trouvée en cc qui concerne Ia protéinurie,
Ia sévérité des lesions histologiques glomérulaires ou les aspects
d'immunofluorescence de l'IgG du C3 et des antigènes anti BSA ou
en rapport avec le fibrinogène (FRA). La formation de croissants
n'est pas entravée. Cette étude montre que l'héparine, a la dose
maximale possible, est inefficace dans Ia prevention des dépôts
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glomerulaires de FRA et dans Ia modification de l'évolution de IC-
GN ou GBM-GN expérimentales chez Ic lapin.
Antiglomerular basement membrane glomerulo-
nephritis (anti-GBM-GN) and immune complex
glomerulonephritis (IC-GN) are the two major types
of immunologic GN [1]. Based on the immuno-
fluorescence findings from several hundred human
renal biopsy specimens, Wilson and Dixon have es-
timated that about 5% of human GN is of the anti-
GBM type, while 70 to 80% is related to the
glomerular localization of immune complexes [2-5].
The primary event in anti-GBM-GN is the bind-
ing of specific antibody to antigenic sites on the
GBM, whereas in IC-GN circulating antigen an-
tibody complexes become entrapped in the GBM,
with injury in both produced by a series of mediator
systems. Little is known of the specific pathologic
role or comparative importance of complement,
leukocytes, platelets, kinins or coagulation in either
anti-GBM-GN or IC-GN; however, there is evidence
that intravascular coagulation and glomerular fibrin
deposition can result in glomerular damage and cres-
cent formation [6-7]. In many humans and animals
with GN, one can demonstrate intraglomerular
material with the staining properties of fibrino-
gen/fibrin (fibrinoid) [7]. By the induction of intra-
vascular coagulation in rabbits, one can produce a
gamut of glomerular histologic changes which re-
semble lesions in human GN [8]. Finally, there are
several reports that anticoagulation at the time of in-
duction of experimental GN can ameliorate the disease.
Most investigators studying anticoagulation have
utilized models of anti-GBM-GN with heparin [9-
13], warfarin [14] or Arvin [15] as the anticoagulant
drug, and not all have found anticoagulation benefi-
cial [12, 13]. As in anti-GBM-GN, the results of an-
ticoagulation in IC-GN are unclear. The classic
models of IC-GN are acute and chronic serum
sickness (AcSS, CSS) in rabbits which also serve as
models for human GN [16]. Only AcSS has been
studied and Baliah and Drummond [17] gave war-
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farm without effect. NZB mice develop a spon-
taneous form of IC-GN which was reportedly im-
proved by heparin administration [18] but unaffected
by warfarin [19].
Because of the variable and conflicting results of
previous anticoagulation trials and the widespread
and poorly controlled use of heparin in human GN,
we have studied the effect of heparin anticoagulation
in rabbits with IC-GN (CSS) and anti-GBM-GN.
Methods
Experimental models. 1) IC-GN. CSS was induced
in 76 male New Zealand white rabbits, weighing 3 kg
each, as previously described [16, 20, 21], using suffi-
cient bovine serum albumin (BSA) to balance an-
tibody production as determined weekly by the P80
technique [22]. Most groups of rabbits received 10 tg
of Escherichia coil endotoxin (Difco Laboratories,
Detroit, Michigan) three hours before the first 10-mg
BSA dose, in order to boost the immune response.
An open renal biopsy was performed 24 hr before
anticoagulation. Histologic specimens were obtained
by biopsy or at autopsy between 8 and 12 weeks of
injection. Survivors were killed at 18 weeks. Fifteen
rabbits were excluded from study: BSA unresponsive-
ness, 7; surgical complications, 5; anaphylaxis, 1;
and pneumonia, 2.
2) Anti-GBM-GN. Anti-GBM-GN was induced in
28 male rabbits, weighing 1 kg each, by the i.v. injec-
tion of a quantitated amount of horse antirabbit
GBM immunoglobulin (Ig) [23] or a predetermined
volume of an Ig fraction of sheep antirabbit GBM
antibody to produce proteinuria within 24 hr [24].
Both anti-GBM antibodies were produced using
purified rabbit GBM as the immunogen [25]. Certain
anti-GBM antibody fractions are nonpathogenic
when injected into neutrophil and complement-
depleted rabbits (neutrophil and complement-
dependent), whereas other antibody fractions are
pathogenic (neutrophil and complement-
independent) [24, 26]. The horse anti-GBM an-
tiserum was found to be neutrophil-independent, and
the sheep, neutrophil-dependent. Since complement's
main role appears to be to attract neutrophils,
neutrophil independence and dependence are im-
munopathologically synonymous with complement
independence and dependence (Cochrane, C. G., per-
sonal communication). An open renal biopsy was
performed before the administration of the anti-
GBM antibody and again at four to five days; at the
time of sacrifice at seven to ten days, an autopsy was
performed.
Control rabbits. Twenty-seven nonheparinized CSS
rabbits which served as control animals were divided
into groups and matched to the heparinized groups
according to their maximum P80 value and their
weeks of receiving BSA injections. Approximately
50% of the control rabbits were treated
simultaneously with the heparinized groups, while
the rest came from earlier experiments which
employed the same CSS protocol. In the anti-GBM-
GN experiments, nonheparinized rabbits receiving
the same dosage of anti-GBM antibody as the
heparinized groups served as controls.
Anticoagulation. In IC-GN after either two, four or
six weeks of BSA injections, heparin (Lipo-Hepin,
Riker Lab., Northridge, CA) treatment began when a
dose of 5000 U every 12 hr was injected sub-
cutaneously (s.c.). Heparin's anticoagulation effect
was monitored by a standard partial thromboplasin
time (PTT) on blood drawn before a heparin injec-
tion. Heparin treatment was discontinued for 24 hr
before and after biopsy. In anti-GBM-GN heparin
was administered in different regimens: 5000 U i.v. or
s.c. 1 hr prior to or concomitant with the anti-GBM
antibody followed by 5000 to 8000 U i.v. or s.c. every
8 or 12 hr for the duration of the experiment. Larger
doses in either model resulted in early death.
Effects of endotoxin and heparin on normal rabbits.
Eight normal rabbits received 10 g of endotoxin i.v.
and two were killed at four two-day intervals; after an
open renal biopsy, four normal rabbits received 5000
U of heparin s.c. every 12 hr for four weeks and were
then killed and renal tissue was obtained.
Effect of heparin in binding of anti-GBM antibody
and hemolytic complement. Four rabbits (1 kg) were
each given 10,000 U of heparin i.v. one hour before
(two rabbits) and simultaneous with (two rabbits) the
injection of 1251 horse antirabbit GBM antibody using
the paired label technique [23]. The acute effect of
heparin administration on hemolytic complement
(CH50) was studied by obtaining serum samples
before and at one, three, five and seven hours after
injecting 5000 U heparin i.v. or s.c. in rabbits (3 kg)
and performing a modified CH50 assay [27].
Histopathology. Hematoxylin-eosin and periodic
acid-Schiff-stained sections of the kidney were
evaluated as to the overall severity of the glomerular
and tubular architectural changes and the presence of
glomerular crescents. Overall severity was deter-
mined by evaluating the following indexes:
glomerular hypercellularity, polymorphonuclear
leukocyte infiltration, G BM thickening, crescent for-
mation, fibrosis, changes in arteriolar walls, necrosis
and tubular atrophy. Each section was graded on a 0
to 4 scale with 0 being no change, 1 being minimal
change, 2 being slight to moderate, 3 being moderate
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to severe and 4 being complete glomerular oblitera-
tion with marked tubular atrophy. Crescents were
defined as any proliferation of the epithelial cells of
Bowman's capsule involving four or more contiguous
cells; a section was not considered to be positive for
crescents unless at least 10% of the glomeruli had
some degree of crescent formation.
Immunofluorescence. Renal tissue for im-
munofluorescence study was "snap" frozen in liquid
nitrogen and stained with antisera specific for rabbit
IgG, third component of complement (C3) and
fibrinogen-related antigen(s) (FRA), including fibrin
[20, 21, 28]. The specificity of the fluorescent reagents
was shown by absorption with their specific antigen.
CSS immunofluorescence was graded on a 0 to 4+
scale [20]. Anti-GBM sections were also graded 0 to
4+ depending on the intensity of the staining with I +
being faint, and 4+, bright staining. FRA staining
was graded on a 0 to 4+ scale depending on the pat-
tern and intensity of the glomerular fluorescence.
Lab procedures. Two-mi blood samples were col-
lected at the time of the subsequent heparin injection
via an arterial puncture and the PTT was determined
by a standard method [29] using Platelin (General
Diagnostics, Morris Plains, NJ) as a thromboplastin
source. Pooled plasma from ten normal rabbits
stored at —70°C was used as a control run
simultaneously with each determination and gave a
PIT value of 27.5 to 32.5 sec. Proteinuria was
measured as previously described [21], Blood urea
nitrogen (BUN) concentrations were determined on
an automatic chemical analyzer (ACA; Dupont
Instruments, Wilmington, DE).
imum P80 value (Table 1). The glomerular
histopathology ranged from a predominant thicken-
ing of the GBM (membranous GN) to marked
proliferation of the mesangial and endothelial cells
with little GBM thickening (proliferative GN) or a
combination of both (mixed membranous and
proliferative GN). The three types of GN were found
at all three levels of antibody response with high an-
tibody responders having slightly more proliferative
GN, and the low, more membranous ON. Heparin
had no effect on the distribution of the three
morphologic types within the IC-GN groups.
There were small semiquantitative differences in
overall histologic severity between heparinized and
nonheparinized rabbits with similar antibody
responses (P80) (Table 1). In the heparinized low-
antibody responders, the histopathologic changes
were more severe (2.3 to 1.6), whereas in heparinized
high responders, changes were least severe. However,
all heparinized groups showed slightly greater overall
histopathologic severity (2.3 to 2.1) than controls.
The ratio of animals with crescent formation involv-
ing greater than 10% of the glomeruli was also similar
at all levels of antibody response and was unaffected
by heparin (Fig. 1, A and B). When renal tissues were
studied by immunofluorescence microscopy, no
quantitative or qualitative differences in the deposi-
tion of IgG (Fig. 1F), C3, BSA and FRA were ap-
parent between the heparin-treated and untreated
groups. FRA staining patterns consisted of either
predominantly endocapillary staining (Fig. 2A), in-
tense focal staining of the glomerular urinary space
(Fig. 2B), a granular-type staining of the GBM (Fig.
Results
Experimental models: General observations. The
course of IC-ON (CSS) in rabbits depends on the
degree of antibody response (when antigen dosage is
adjusted to balance antibody response). Rabbits with
high antibody levels have a fulminant ON and usual-
ly die within 6 to 10 weeks; those with low antibody
levels have a protracted course lasting 12 to 18 weeks.
The severity of anti-GBM-GN depends on the
amount of anti-GBM antibody administered, and in
our experiments the course was rapidly progressive
leading to death within seven to ten days. Heparin-
treated rabbits with IC-ON and anti-OBM-GN had
courses similar to those of the untreated rabbits with
no apparent differences in longevity or severity of the
uremic syndromes.
Immunopathologic observations. 1) IC-GN. Rabbits
with IC-GN were divided into low, moderate and
high antibody responders depending on their max-
Table 1. Immune complex glomerulonephritis: Histologic
comparison of heparin and control groupsa
Heparin,
5000 U
s.c. 12 hr
Animals,
N
Crescents"
Overall
severity
P80 10—40 HeparinControl
4
10
3/4
6/10
2.3
1.6
P80 40—80 Heparin 20 10/20 2.4Control 9 5/9 2.1
P80>80 HeparinControl
10
8
5/10
7/8
2.3
2.5
a immunofluorescence patterns of IgG, BSA, C3 and FRA were
similar in heparin and control groups.
Crescent formation was defined as the proliferation of four or
more contiguous parietal epithelial cells involving at least 10%
of the glomeruli.
Overall severity represented the mean value of the following:
G BM thickening, polymorphonuclear leukocyte infiltration,
glomerular hypercellularity, changes in arteriolar walls, necrosis
and tubular atrophy as judged on a 0 to 4+ scale with 4+
being the greatest abnormality.
Fig. 1. A. Photomicrograph of a glomerulus from IC-GN rabbit 3437 after six weeks of daily BSA injections taken before the onset of
proleinuria and the start of heparin administration (hematoxylin-eosin, X320). Note focal mesangial proliferation (arrows) typical of early
daily injection CSS glomerulonephritis. B. Specimen from a repeat biopsy of IC-GN rabbit 3437 (Fig. IA) taken six weeks later during
which heparin had been given in a dosage of 5000 U every 12 hr (hematoxylin-eosin, X320). Note the extensive proliferative glomerulo-
nephritis with crescent formation (arrows) indistinguishable from that in the nonheparinized IC-GN controls. C. Biopsy specimen showing
normal glomerular architecture in rabbit 5465 taken before the administration of anti-GBM antibody (hematoxylin-eosin, X320). D. Specimen
of a repeat biopsy of rabbit 5465 (Fig. IC) taken seven days later after administration of anti-GBM antibody and heparin, 5000 U every
eight hours (hematoxylin-eosin, x320). Note proliferative glomerulonephritis and crescent formation (arrows) similar to that present in
a nonheparinized anti-GBM-GN control. E. Glomerulus from a heparinized anti-GBM-GN rabbit demonstrating eosinophilic material
filling Bowman's space corresponding to the presence of FRA in Fig. 2D (hematoxylin-eosin, X320). F. Granular deposits of lgG (accompanied
by BSA and C3) as seen in the IC-GN induced in the CSS rabbits (fluorescein isothiocyanate-conjugated antirabbit IgG, X250). G. Smooth
linear deposits of heterologous anti-GBM antibody as seen in the anti-GBM-GN rabbits (fluorescein isothiocyanate-conjugated antihorse
IgG, X250).
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Fig. 2. Patierns of FRA deposits observed in IC-GN and anti-GBM-GN of heparin-treated
rabbits (fluorescein isothiocyanate-conjugated goat antirabbit fibrinogen antibody, X250). A-B.
Typical ERA staining occurring in IC-GA' rabbits with proliferative histologic changes. Deposits
in A were largely confined to glomerular capillary lumens (arrows); and in B, with advanced
damage, intense focal FRA accumulation is apparent. C. FRA deposition tended to be
confined to the thickened glomerular capillary walls (arrows) in IC-GN rabbits with
membranous glomerular changes. D. Heavy ERA deposits (arrows) were observed in the areas
of extravosalion of eosinophiiic material seen in anti-GBM-GN animals (Fig. JE).
2C) or a combination of the various patterns. FRA
deposits were observed in glomeruli with crescent for-
mation; however, similar deposits were seen unac-
companied by crescent formation.
2) Anli-GBM-GN. Rabbits with anti-GBM-GN
were separated into groups which received either a
large dose (2320 Lg) or a smaller dose (405 tg) of
neutrophil-independent horse antibody or a dose of
neutrophil-dependent sheep antibody calculated to
produce immediate proteinuria (1.5 ml) (Table 2).
The rabbits receiving the high and low dose of horse
antibody were further subdivided into two groups
which received the same heparin dosage by different
routes, Lv. or s.c. Both types of antibody produced a
rapidly progressive lesion involving virtually 100% of
the glomeruli characterized by cellular proliferation,
necrosis and crescent formation with extravasation of
eosinophilic material into Bowman's space (Fig. 1, C,
D and E).
The heparin-treated group's overall histologic
changes were greater than the untreated groups' (2.8
to 2.4) at both doses of horse antibody (Table 2).
Crescents were present in all groups and the incidence
appeared similar between heparinized and control
rabbits (Fig. 1, C and D). Comparison of heparinized
and control rabbits with anti-GBM-GN revealed no
differences in the immunofluorescence patterns of
horse or sheep IgG (Fig. IG), host IgG and C3 or
FRA. FRA deposits in anti-GBM-GN were similar
to IC-GN except for a unique pattern (Fig. 2D) that
corresponded to the eosinophilic lakes seen to be fill-
ing Bowman's space in the hematoxylin-eosin-stained
sections (Fig. 1E).
3) Renal function. Rabbits with IC-GN usually
developed proteinuria after six weeks of BSA injec-
tions; those with anti-GBM-GN had proteinuria
within 12 hr of receiving the anti-GBM antibody. An
occasional animal with IC-GN and a high antibody
response developed proteinuria in three to four
weeks. Heparinized rabbits and controls with IC-GN
and anti-GBM-GN displayed no important
differences in time of onset or eventual severity of
Ileparin ('ontro!
protein ura• proton uria
lleparin Control
BUN • BUN
I
345678345678
Weeks
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Table 2. Anti-GBM glomerulonephritis: Histologic comparison of heparin and control groups
1-leparin,
5000 U
Anti-GBM
used
Animals,
N Crescents"
Overall
.
severltye
Heparin
Control
s.c., 8 hr
—
2320 sg"
2320sg
5
5
3/5
2/5
2.2
2.8
Heparin
Heparin
Control
iv., 8 hr
s.c., 8 hr
—
405 Mgd
405,ug
405 zg
2
2
3
2/2
1/2
2/3
2.0
2.5
2.3
Heparin
Control
s.c., 12 hr
—
1.5 ml"
1.5 ml
6
5
5/6
5/5
2.9
3.3
Immunofluorescence patterns of lgG, C3 and FRA were similar in heparin and control groups.
Crescent formation was defined as the proliferation of four or more contiguous parietal epithelial cells involving at least 10% of the
glomeruli.
Overall severity represented the mean value of the following: GBM thickening, polymorphonuclear leukocyte infiltration, glomerular
hypercellularity, changes in arteriolar walls, necrosis and tubular atrophy as judged on a 0 to 4+ scale with 4+ being the greatest ab-
normality.
Horse antirabbit GBM antibody (neutrophil-independent; see text).
Sheep antirabbit GBM serum (neurophil-dependent; see text).
their proteinuria (Figs. 3 and 4). Comparison of
BUN values (Fig. 3) showed only what appeared to
be higher terminal values for the heparinized group.
Heparinization also did not affect BUN concentra-
tions in the anti-GBM-GN groups.
4) Anticoagulation. PTTs in representative rabbits
with IC-GN and anti-GBM-GN were drawn just
before the subsequent heparin injection. Clinically, a
PIT prolonged to 1½ to 2½ times the control is con-
sidered to be a therapeutic level of heparin anti-
coagulation [301. On the heparin dosages used, the
majority of the rabbits maintained values between
two and four times the control value of 32 sec. Oc-
casionally, an animal's PTT would be between con-
trol and two times control value, but none returned
Fig. 3. Weekly comparison of proteinuria and blood urea nitrogen
(BUN) values in heparinized (left) and nonheparinized control
(right) IC-GN rabbits. BUN values in parentheses are greater than
100.
to the control level. The heparin dosages used were
the highest that could be given to nephritic rabbits for
several weeks without producing fatal complications.
In a separate study, four of six IC-GN rabbits given
8000 U s.c. every 12 hr died within 48 hr. Normal
rabbits tolerated the same dosage for two weeks
with only transient drops in their hematocrit values.
Thus, nephritic rabbits appeared to have an enhanced
susceptibility to heparin's effects on bleeding.
5) Effect of heparin and endotoxin on normal rabbits,
Renal sections from rabbits given 5000 U of heparin
s.c. every 12 hr for four weeks showed normal
glomerular and tubular architecture. Rabbits given
10 tg of endotoxin i.v. had marked glomerular ac-
cumulation of neutrophils and questionable
mesangial thickening when examined at 24 and 48 hr,
but after seven days the glomeruli returned to nor-
mal.
6) Effect of heparin on binding of anti-GBM an-
tibody and Cl-I50 concentrations. Paired label experi-
ments showed that 2.5% of the isolated Ig from the
Fig. 4. Daily proteinuria values in heparinized (left) and non-
heparinized (right) anti-GBM-GN rabbits. Values in parentheses are
greater than 1000.
I leparth Control
proteinurla proLelnurta
l000f- . s I
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c)
260
220
180
140
100
60
20
Time, hr
Fig. 5. Temporal effects of subcutaneous (s.c.) and intravenous
(i.v.) administration of heparin on normal rabbits' hemolytic
complement as measured in modified CH50 units (see text).
horse anti-GBM antiserum was specific for rabbit
GBM. Administration of heparin one hour prior to
or concomitant with the Ig did not alter the percen-
tage of GBM specific antibody, showing that heparin
did not interfere with the binding of the antibody to
the GBM.
Heparin produced acute but transient depression
of the CH50 values in both normal and nephritic rab-
bits (Fig. 5). Depression by heparin given i.v. was
greater than by s.c. administration, but in both cases
the CH50 returned to normal by five to seven hours
suggesting a dose-response effect. CH50 values in
nephritic rabbits receiving heparin for at least six
weeks were normal if drawn prior to a heparin injec-
tion.
Discussion
In experimental GN, the nature and severity of the
lesions vary depending on the concentrations of cir-
culating antigen-antibody complexes produced and
the dosage and type of anti-GBM antibody injected,
as well as the individual host's response. Theoretical-
ly, it should be easiest to detect effects of therapy
when a uniform and generalized glomerular involve-
ment is induced as in our experiments by 1) adjusting
the BSA dosage to balance the individual antibody
response and ensure maximal formation of cir-
culating nephritogenic complexes, and 2) using a
sufficient amount of anti-GBM antibody to produce
immediate involvement of all glomeruli. With 100%
glomerular involvement in both our IC-ON and anti-
GBM-GN models, we found no evidence that
heparin had a therapeutic effect on the severity of the
glomerular lesions, incidence of crescent formation
or impairment of renal function as judged by
measurements of proteinuria and BUN.
Obvious difficulties in comparing the results of
previous anticoagulation studies arise from the use of
different anticoagulants and the variation in the
severity of the experimental GN model. Immediate
anti-GBM injury is produced by injecting an ap-
propriate amount of a heterologous anti-GBM an-
tibody, whereas delayed injury results from the host's
immune response to the already GBM-bound an-
tibody and begins after seven to ten days [1].
Klinerman [10] and Halpern et al [11] induced a
delayed form of anti-GBM-GN with only mild
glomerular lesions involving some but not all
glomeruli and reported that hepariri reduced
glomerular damage and crescent formation. In addi-
tion, Halpern et al reported marked improvement in
proteinuria and BUN retention. In contrast, Bone et
al [12] and Briggs, Kwaan and Potter [13] induced an
immediate type of anti-GBM-GN and found no
protective effect of heparin on the development of
glomerular lesions, crescent formation or proteinuria
or BUN elevation. Vassalli and McCluskey [14]
found that warfarin anticoagulation did not affect
proteinuria concentrations in an immediate form of
anti-GBM-GN but prevented crescent formation and
glomerular hyalinization. Naish et al [15], using
Arvin to deplete circulating fibrinogen concentra-
tions, reported reduced glomerular involvement,
crescent formation and BUN concentrations in a
delayed type of anti-GBM-GN. In our study, a uni-
form type of immediate anti-GBM-GN was pro-
duced, and despite maximum permissible heparin
dosages, no histological or functional benefits were
noted. One can conclude that in general those in-
vestigators inducing milder and more variable forms
of anti-GBM-GN found beneficial effects of an-
ticoagulation while those inducing more constant and
severe forms, as we did, found little or no effect.
Comparisons of anticoagulation studies using
different models of IC-ON are even more difficult
than in anti-GBM-GN. Acute serum sickness, a tran-
sient, proliferative GN, was not affected by warfarin
administration [17]. In chronic forms of IC-ON such
as found in NZB mice, the results of anticoagulation
have not been consistent. Lambert [18] reported a
beneficial effect of heparin on glomerular histology
while McGiven [19], using warfarin, found no im-
provement in glomerular disease or fibrin deposition
as judged by histological, immunofluorescence and
electron microscopic observations. We found no
benefit from heparin anticoagulation in our model of
chronic IC-GN.
°- 5000 U S.C.
.-—-. 5000 U i.v.
1 3 5 7
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Heparin was used in our study because it is a po-
tent, clinically useful anticoagulant which is easy to
administer and has an immediate onset of action. Its
anticoagulant effect is readily monitored and easily
terminated. Heparin's main effect is to enhance a
plasma alpha-2-globulin which acts as an an-
tithrombin, thus blocking the conversion of
fibrinogen to fibrin [30]. The heparin dosage used in
our experimental studies was the highest amount that
did not lead to severe bleeding complications, as
noted by Vassalli and McCluskey [14], who reported
that 26 of 34 warfarin-treated rabbits died of hemor-
rhage. The doses given our rabbits with anti-GBM-
GN were also higher than those used by other in-
vestigators who had found heparin to be beneficial
[9—11].
Reported beneficial effects of heparin in anti-
GBM-GN have been attributed by some to in-
terference with the antibody's binding to the GBM or
an anticomplementary effect. Our experiments
showed that heparin did not affect the amount of an-
tibody binding to the GBM or have a therapeutically
important anticomplementary effect, even though
heparin acutely depressed CH50 concentrations with a
time course reminiscent of heparin's effect on the
PTT. When heparin was mixed with normal rabbit
serum, 0.1 to 2.0 U of heparin/mi enhanced total
hemolytic complement in vitro, whereas concentra-
tions greater than 2.0 U/mI diminished hemolysis
(Wilson, C.B., unpublished observations). Heparin
treatment also produced no differences in the
nephritogenic effects of the neutrophil-independent
horse and neutrophil (and presumably complement)
dependent sheep antirabbit GBM antibodies or in the
glomerular C3 deposits present in the heparin-treated
and control animals.
Heparin did not affect the deposition of FRA in
either of our GN groups, which suggests that FRA
generation occurred independently of classic heparin-
sensitive coagulation pathways as previously sug-
gested by Briggs et al [13]. Hoyer, Michael and Hoyer[31] recently observed dissociation between
glomerular deposition of fibrin and antihemophilic
factor, suggesting fibrin deposition by other than
systemic coagulation mechanisms, Possibly, platelets
interacting with antigen-antibody complexes and/or
damaged endothelium or GBM initiate in-
traglomerular clotting [32, 33]. Of interest is that
reports of amelioration of human GN with a com-
bination of anticoagulant drugs have included
medications that interfere with platelet activity [34].
Mersky recently summarized the reasons for believ-
ing that disseminated intravascular coagulation may
arise from processes other than thrombin-induced
alterations of fibrinogen [35]. There is a growing list
of factors which can precipitate or polymerize
fibrinogen in the absence of thrombin: a proteolytic
enzyme isolated from human aorta, glycoprotein
platelet factor-4, staphylococcal clumping factor, a
rabbit polymorphonuclear leukocyte lysozomal pro-
tein fraction and certain endothelial cell-derived
kinases and cathepsins [35]. There is no reason to
believe that heparin's anticoagulant effect influences
any of these factors; and some patients with dis-
seminated intravascular coagulation indeed fail to
respond to heparin therapy [35]. Nonthrombin-
related fibrin formation would also be one explana-
tion for the apparent inability of heparin to block
glomerular FRA deposition. Indeed, reported benefi-
cial effects of Arvin [15], which depletes fibrinogen, in
anti-GBM-GN may relate to the prevention of fibrin
accumulation produced by other than systemic
coagulation pathways.
Our study does not prove or disprove the
pathogenic importance of glomerular fibrin ac-
cumulation in immunologic renal disease. However,
it does show that heparin in maximum permissible
doses has no demonstrable therapeutic effect on IC-
GN or anti-GBM-GN and supports the concept that
glomerular fibrin deposits result from processes other
than systemic coagulation.
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